Simulations Plus

The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for Altaris’s takeover of Simulations Plus has expired, thereby satisfying a regulatory condition for closing. Completion of the transaction still depends on approval by Simulations Plus’s shareholders, regulatory approvals in France and other customary closing conditions. A closing is expected in the second half of 2026, subject to remaining conditions or their waiver; financial details were not disclosed. » More on de.investing.com

Simulations Plus will release results for the quarter ended May 31, 2026 on July 9, 2026. Analysts see an average EPS of $0.233 per share versus -$3.35 a year earlier and quarterly revenue of about $20.9 million (up 2.65% from $20.4 million). For the current fiscal year analysts expect an average EPS of $0.868 and revenue of roughly $81.7 million versus $79.2 million in the prior year. » More on finanzen.net

Altaris affiliates will acquire Simulations Plus for $18.50 per share in an all-cash transaction valuing the company at about $375m, a 26% premium to the 60-day VWAP as of June 15, 2026. The deal, unanimously approved by Simulations Plus' board, is subject to shareholder and regulatory approvals and is expected to close in Q4 2026, after which Simulations Plus will be a privately held subsidiary and delisted from Nasdaq. Altaris plans to combine Simulations Plus with portfolio company Chemical Computing Group to create a broader biosimulation platform for drug discovery and development. » More on finance.yahoo.com

Simulations Plus is partnering technically with NVIDIA to integrate GPU-accelerated computing and AI capabilities into its modeling workflows for pharmacokinetics, pharmacodynamics and quantitative systems pharmacology. The goal is to speed up simulation cycles, enable parallel exploration of model structures and parameter fitting; tests show time savings of up to 75% for end-to-end modeling. NVIDIA is providing compute infrastructure, the BioNeMo platform and a pharmaceutical partner network, while Simulations Plus contributes its simulation engines and industry expertise. After the announcement, SLP shares rose by around 12% and InvestingPro rates the stock as significantly undervalued. » More on de.investing.com

Simulations Plus has launched a funded research collaboration with Lonza and the FDA to develop predictive in vitro/in vivo models for amorphous solid dispersions, aiming to enable pharmacokinetic prediction and virtual bioequivalence assessments. Lonza will conduct experimental dissolution testing, while Simulations Plus will use DDDPlus and GastroPlus for modeling; the work is partially funded by the FDA and is based on non‑proprietary data from approved products. The project seeks to reduce reliance on clinical bioequivalence studies; financials show the company recently reported a loss but is considered undervalued, has strong liquidity, and analysts expect it to return to profitability this year. » More on de.investing.com